EP0848610A1 - Utilisation d'un derive de carbostyril pour inhiber la carcinogenese - Google Patents

Utilisation d'un derive de carbostyril pour inhiber la carcinogenese

Info

Publication number
EP0848610A1
EP0848610A1 EP96927200A EP96927200A EP0848610A1 EP 0848610 A1 EP0848610 A1 EP 0848610A1 EP 96927200 A EP96927200 A EP 96927200A EP 96927200 A EP96927200 A EP 96927200A EP 0848610 A1 EP0848610 A1 EP 0848610A1
Authority
EP
European Patent Office
Prior art keywords
carbostyril
inhibiting carcinogenesis
salt
agent
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96927200A
Other languages
German (de)
English (en)
Inventor
Toshio Takahashi
Tetsuro Yamane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP0848610A1 publication Critical patent/EP0848610A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to an agent for inhibiting carcinogenesis, specifically, it relates to an agent for inhibiting carcinogenesis of the digestive tract cancer. More particularly, the invention relates to an agent for inhibiting carcinogenesis comprising, as the active ingredient, a carbostyril derivative represented by the following general formula (I),
  • R is a halogen atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom) ; the substituted position of the substituent in the carbostyril skeleton is 3- or 4-position in the carbostyril skeleton; and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single bond or a double bond]; or a salt thereof, preferably 2-(4-chlorobenzoylamino)-3-(2-quinolon-4- yl)propionic acid or salt thereof.
  • Patent Application Kokai (Laid-open) No. 3-74329, and processes for producing those carbostyril derivatives having optical activities are described in Japanese
  • Patent Application Kokai (Laid-open) No. 3-145468.
  • carbostyril derivatives of the present invention inhibitory effect of carbostyril derivatives of the present invention on reactive oxygen metabolites is described in Japan. J. Pharmacol., Vol. 49, pp. 441-448 (1969), and the protectability of gastric mucous membrane by carbostyril derivatives of the present invention is described in Folia Pharmacol. Japon., Vol. 97, pp. 371-380 (1991). Furthermore, the usefulness of carbostyril derivatives as agents for curing diabetes mellitus is described in International Publication No. WO 92/21342, the usefulness of carbostyril derivatives as agents for protecting intestinal mucosa from disorders is described in International Publication No.
  • cancers means cancers originated from the epitheliums existed in various parts of the body, for example, cancers originated from epitheliums of the skin, the tongue, the pharynx, the trachea, as well as cancers of the digestive tracts, such as the esophagus, the stomach, the duodenum, the small intestine and the large intestine.
  • the agents for inhibiting carcinogenesis of the present invention can be prepared into various forms of common pharmaceutical preparations by formulating the carbostyril derivative represented by the general formula (I) or a salt thereof.
  • the pharmaceutical preparations are prepared by formulating with commonly employed diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants and the like.
  • the pharmaceutical preparations can be shaped into various forms depending upon the curing purposes, thus, typical examples of the forms are tablets, pills, powders, liquid medicines, suspensions, emulsions, granules, capsules, suppositories, injection preparations (liquid, suspension and the like), aerosol preparations, syrup preparations and preparations for external use and the like. Further, sustained release preparations can also be prepared by formulating with suitable resins.
  • any known carriers which are used widely in this field can be applied, for example, excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrrolidone and the like; disintegrators such as dry starch, sodium alginate, agar powder, laminarin powder, sodium hydrogen-carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglycerides of stearic acid, starch, lactose and the like; disintegration inhibitors such as white sugar, stearin, cacao butter, hydrogenated oils and the like; absorption accelerators such as quaternary
  • the tablets can be prepared in the form of common coated tablets, for example, sugar-coated tablets, gelatin film-coated tablets, enteric film- coated tablets, film-coated tablets, or in the form of double-layers tablets, multiple-layers tablets and the like.
  • any known carriers which are widely used in this field can be applied, for example, excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc and the like; binders such as arabic gum powder, tragacanth gum powder, gelatin, ethanol and the like; and disintegrators such as laminarin, agar-agar and the like can be exemplified.
  • excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc and the like
  • binders such as arabic gum powder, tragacanth gum powder, gelatin, ethanol and the like
  • disintegrators such as laminarin, agar-agar and the like can be exemplified.
  • any known carriers which are widely used in this field can be applied, for example, polyethylene glycols, cacao butter, higher alcohols, esters of higher alcohol, gelatin, semi-synthesized glycerides and the like can be exemplified.
  • any known diluents which are widely used in this field can be applied.
  • water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, fatty acid esters of polyoxyethylene sorbitan and the like can be exemplified.
  • sodium chloride, glucose or glycerin may be contained therein.
  • a dissolving adjuvant, a buffer solution, an analgesic agent and the like which are commonly used may be contained therein.
  • a coloring agent, a preservatives, a perfume, a flavoring agent, a sweetening agent and other medicines may be contained therein.
  • External preparations are prepared in the form of common pharmaceutical preparations for external use.
  • common pharmaceutical preparations for external use are including, for example, a liquid medicine, a medicinal oil, a lotion, a liniment, an oleoginous ointment, an emulsion type ointment, such as O/W type hydrophilic ointment and W/O type water-absorbing ointment, a water-soluble ointment, a pasta, a plaster, a patch, a cream, an emulsion and the like, and these forms of pharmaceutical preparations for external use are not restricted within the scope of these examples.
  • Each one of these forms of pharmaceutical preparations for external use can be prepared by common methods.
  • various base materials which are widely used in this field can be also applied.
  • at least one oleoginous base can be used singly, or mixture of two or more of them can be used widely; or at least one water- soluble ointment base can be used singly, or mixture of two or more of them can be used widely.
  • these ointment base are fats and oils such as peanut oil, sesame oil, soybean oil, safflower oil, avogado oil, sunflower oil, corn oil, rapeseed oil, cotton seed oil, castor oil, camellia oil, coconut oil, olive oil, poppy seed oil, cacao butter, beef tallow, lard, wool fat and the like; modified bases obtained by subjecting these fats and oils to chemical changes such as hydrogenation; mineral oils such as petrolatum, paraffin, silicone oil, squalane and the like; higher fatty acid esters such as isopropyl myristate, n-butyl myristate, isopropyl linoleate, acetyl ricinoleate, stearyl ricinoleate, propyl ricinoleate, isopropyl ricinoleate, isobutyl ricinoleate, heptyl ricinoleate, diethyl sebac
  • a geling agent such as a preservative, an antioxidant, a buffer solution, a pH controlling agent, a wetting agent, an antiseptic agent, a coloring agent, a flavoring agent, a pigment, a thickening agent, a metal chelating agent and the like.
  • Aerosol type preparations can be prepared generally by formulating a sterilized solution or suspension of the carbostyril derivative of the general formula (I) with a propellant.
  • a propellant for example, any one of known diluents which are commonly used in this field can also be used, thus the diluents which are exemplified in formulating the injection preparations can be used.
  • any one of the propellants which are commonly used in this field can also be used, thus, liquefied gas propellants such as chlorofluorocarbons like Flon-12 (general term of dichlorodifluoromethane) or Flon-123 (general term of trifluorodichloroethane) ; compressed gas propellants such as nitrogen gas, carbon dioxide gas and the like can be exemplified.
  • the aerosol type preparations may further contain a common solubilizing adjuvant, a buffering agent, and the like, and if necessary, a coloring agent, a preservative, a perfume, a flavoring agent, a sweetening agent may be added thereto.
  • the amount of the carbostyril derivative of the general formula (I) or salt thereof to be contained in the agent for inhibiting carcinogenesis according to the present invention is not particularly restricted and can be selected from a wide range, and the amount may be generally selected within the range of 1-70% by weight, preferably 5-50 % by weight.
  • Method for administering the agent of the present invention is not particularly restricted except that the case selected to the specific treating purpose.
  • the method is decided depending upon the form of pre ⁇ paration, the age of patient, the distinction of sex and other conditions, the degree of disease condition of the patient and others.
  • tablets, pills, a liquid medicine, a suspension, an emulsion, granules, a syrup and capsules are administered orally.
  • An injec ⁇ tion preparation is intravenously administered singly or in combination with common auxiliary solutions such as glucose solution and/or amino acid solution, in case of necessity, it is singly administered intramuscularly, intradermally, subcutaneously or intraperitoneally.
  • a suppository is administered intrarectally.
  • An external preparation is coated on the diseased part.
  • Dosage of the agent for inhibiting carcino- genesis of the present invention may be suitably selected depend upon the age of patient, the distinction of sex and other conditions, as well as the degree of disease condition of the patient and other related factors, and generally the amount of carbostyril derivative of the general formula (I) or salt thereof may be 0.6 to 50 mg per 1 kg of the body weight per day.
  • the desirable content of the effective ingredient in each unit of administration form may be 10 to 1,000 mg.
  • Citric acid 1. .0 g
  • Polyethylene glycol (Carbowax 6000) 45. .0 g
  • the mixture was sieved through a No. 60 screen.
  • the resulting sieved mixture was wet-granulated with an ethanol solution containing polyvinyl pyrro ⁇ lidone, Carbowax 1500 and Carbowax 6000.
  • ethanol was added to convert the mixture into a paste-like mass.
  • Corn starch was added, and mixing operation was continued until uniform particles were formed.
  • the resulting particles were passed through a No. 10 screen, then placed in a tray, and were dried in an oven at 100°C for 12-14 hours. The dried particles were sieved through a No. 16 screen. Next, dry sodium lauryl sulfate and dry magnesium stearate were added to the resulting particles.
  • the mixture was compressed into core tablets of the desired shape by using a tablet machine.
  • the resulting core tablets were treated with a varnish and then talc was sprayed thereon for preventing from moisture absorption.
  • undercoat layer was coated. Sufficient number of varnish coatings were conducted to the core tablets so as to make them suitable for internal use. Formation of undercoat layer and smooth coating were conducted to make the coated tablets having completely round and smooth surface. Color coating was conducted until the desired color surface was obtained. After drying, the coated tablets were polished to obtain tablets of uniform gloss.
  • Polyethylene glycol (mol. wt.: 4000) 0.3 g
  • N-Ethyl-N'-nitro-N-nitrosoguanidine which is known as a carcinogenic substance, was administered to the mice to produce cancer of the duodenum, then 2-(4-chlorobenzoylamino)-3- (2-quinolon-4-yl)propionic acid (general name: Rebamipide) was administered as test compound to the test mice to examine the activity for inhibiting carcinogenesis.
  • the test mice were classified into three groups of A, B and C (each one of the groups is con- sisting of 30 mice). The all of the test mice were given freely the drinking water which contains ENNG in the concentration of 100 mg/liter for 4 weeks. Thereafter, one solid feed in which the amount of test compound of Rebamipide is controlled to keep in the rate of 20 mg/kg/day were given to the mice of Group A from 5th to 16th week, and another solid feed in which the amount of test compound of Rebamipide is controlled to keep in the rate of 50 mg/kg/day were given to the mice of Group B for from 5th to 16th week.
  • test mice of Groups of A, B and C were given tap water freely, then the duodenums of the test mice were sacrificed on the 16th week after the administration of the test compound, and the effect for inhibiting carcinogenesis performed by the test compound were examined.
  • the average incidences of carcinogenesis were 0.84 ⁇ 0.86 in Group A, 0.68 ⁇ 0.87 in Group B and 1.21 ⁇ 1.27 in Group C, respec- tively, thus the carcinogenesis were inhibited in the test mice of Groups A and B which were administered with carbostyril derivative of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne un agent d'inhibition de carcinogenèse, ou l'un de ses sels, lequel agent comprend, en qualité d'ingrédient actif, un dérivé de carbostyryle correspondant à la formule générale (I) où R est un atome halogène.
EP96927200A 1995-09-06 1996-08-20 Utilisation d'un derive de carbostyril pour inhiber la carcinogenese Withdrawn EP0848610A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP228889/95 1995-09-06
JP7228889A JPH0971532A (ja) 1995-09-06 1995-09-06 発癌抑制剤
PCT/JP1996/002319 WO1997009045A1 (fr) 1995-09-06 1996-08-20 Utilisation d'un derive de carbostyril pour inhiber la carcinogenese

Publications (1)

Publication Number Publication Date
EP0848610A1 true EP0848610A1 (fr) 1998-06-24

Family

ID=16883451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96927200A Withdrawn EP0848610A1 (fr) 1995-09-06 1996-08-20 Utilisation d'un derive de carbostyril pour inhiber la carcinogenese

Country Status (7)

Country Link
EP (1) EP0848610A1 (fr)
JP (1) JPH0971532A (fr)
KR (1) KR19990043995A (fr)
CN (1) CN1195987A (fr)
AU (1) AU705751B2 (fr)
CA (1) CA2228898A1 (fr)
WO (1) WO1997009045A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681360B1 (ko) 2003-07-30 2007-02-12 오츠카 세이야쿠 가부시키가이샤 타액분비 촉진용 카르보스티릴 유도체
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
US9248196B2 (en) 2011-02-25 2016-02-02 Nuformix Limited Rebamipide complexes and cocrystals
KR101395984B1 (ko) * 2011-10-21 2014-05-16 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
DE102012218773A1 (de) * 2012-10-15 2014-04-17 Continental Automotive Gmbh Verfahren und Einrichtung zur Messung eines Stroms durch einen Schalter
EP3797773A1 (fr) * 2019-09-03 2021-03-31 Square Power Ltd Rebamipide destiné à être utilisé dans la prévention et le traitement du cancer
CN110974968B (zh) * 2019-12-11 2021-03-26 中山万远新药研发有限公司 含有喹诺酮类化合物的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6010031B2 (ja) * 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体の製造法
DK0552373T3 (da) * 1991-07-03 1999-12-27 Otsuka Pharma Co Ltd Apoptoseregulator
TW227558B (fr) * 1992-05-14 1994-08-01 Otsuka Pharma Co Ltd
JP2872546B2 (ja) * 1992-11-26 1999-03-17 大塚製薬株式会社 腸粘膜障害保護剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9709045A1 *

Also Published As

Publication number Publication date
CA2228898A1 (fr) 1997-03-13
KR19990043995A (ko) 1999-06-25
AU705751B2 (en) 1999-06-03
CN1195987A (zh) 1998-10-14
JPH0971532A (ja) 1997-03-18
AU6710096A (en) 1997-03-27
WO1997009045A1 (fr) 1997-03-13

Similar Documents

Publication Publication Date Title
TW576743B (en) Extended release formulations of erythromycin derivatives
EP2033633A2 (fr) Inhibiteurs d'oxydation d'acide gras partiel dans le traitement d'une insuffisance cardiaque congestive
US20040234593A1 (en) Diphenhydramine tannate compositions and methods of use
KR20130009906A (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 경구용 고형 제제 및 이의 제조방법
AU705751B2 (en) An agent for inhibiting carcinogenesis
KR100366130B1 (ko) 항과혈당증작용을지닌약제
PT97550B (pt) Processo para a preparacao de uma composicao farmaceutica contendo ibuprofeno, e uma prostaglandina
US6300343B1 (en) Method of treatment
AU668267B2 (en) Method for preventing and treating disturbances of intestinal mucous membrane
KR100192534B1 (ko) 소마토스타틴 분비증가제와 분비저하 억제제
AU2003217704A1 (en) Diphenhydramine tannate compositions and methods of use
JP2812998B2 (ja) 胃炎治療剤
AU740749B2 (en) Method of treatment
JP2702284B2 (ja) ソマトスタチン増加用またはソマトスタチン低下抑制用薬剤
JPH045233A (ja) 高脂血症予防及び治療剤
JPH0827000A (ja) 悪阻による諸症状の予防または治療薬
JPH01261329A (ja) １，６，１２−トリオキサ−９−アザ−５−ゲルマスピロ［４．７］ドデカン−２−オン誘導体を有効成分とする免疫賦活剤及び製剤組成物
JPH0827001A (ja) 術後嘔吐の予防または治療薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990621